Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

NCT01763164 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

402

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic or Unresectable Cutaneous Melanoma

Interventions

DRUG: MEK162
DRUG: Dacarbazine

Sponsor

Pfizer